雷贝拉唑根除幽门螺杆菌的最小成本分析

目的：比较3种三联疗法根除幽门螺杆菌（却）感染的疗效和成本。方法：86例经胃镜确诊为胃或十二指肠溃疡伴阳性患者分为3组，RCF7：雷贝拉唑（R）10mg bid，、克拉霉素（C）0．5g bid、呋喃唑酮（F）0．2g bid联用7d；RAC7：R20mg bid，阿莫西林（A）1．0g bid、C0．5g bid，联用7d；RAC5：R20mg bid，A1．0g bid，C0．5g bid，联用5d。联合治疗结束后再分别予以雷贝拉唑10mg，qd，整个疗程3周。成本分析采用药物经济学的最小成本分析法。结果：3组却根除率和溃疡愈合率差异无显著性（P〈0．05），但治疗成本不同。结论：RAC5组的成本最低。

An Analysis of Minimal Cost of Rabeprazole in Eradication of Helicobacter Pylori

Objective: To compare the effect and cost of 3 therapeutic schemes of triple therapy in eradication of helicobacter pylori(Hp). Method:86 cases who were diagnosed as gastric ulcer or duodenal ulcer by gastroscope with Hp positive were divided into three groups. The RCF7 group received rabeprazole(R) 10 mg + clarithromycin(C)0. 5 +fura-zolidone(F) 0. 2, bid,for 7 d, and the RAC7 group or the RAC5 group was provided with RIO mg + amoxicilin(A) 1.0 + C 0.5,bid, for 7 d or 5 d, respectively. The three groups were provided with RIO mg, qd after the combination treatment was finished. The period of the treatment persisted 3 weeks. The data were evaluated by using the cost minimization analysis of pharmacoeconomic. Result:There was no statistically significant difference for the Hp eradication rates and the ulcer healing rates of the three groups( P > 0. 05 ) , but the costs of the therapeutic schemes were different. Conclusion:The costs showed that the RAC5 group's cost was the least, and therefore suitable for patients.